How to use Tevimbra (Tislelizumab-jsgr)

Tevimbra (Tislelizumab-jsgr) is an immune checkpoint inhibitor that is widely used to treat adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), especially those who have failed to respond to systemic chemotherapy that does not contain PD-(L)1 therapy. As a new type of targeted drug, Tevimbra's medication method is very important and needs to be conducted under the guidance of experienced doctors to ensure patient safety and treatment effectiveness.

Before using TevimbraDoctors will conduct a comprehensive assessment of the patient, including medical history, physical condition and previous treatment experience, to determine whether the patient is suitable for using the drug. Tevimbra is available by prescription only and is available as an injection, a clear to slightly opalescent, colorless to slightly yellow solution, usually in 100 mg/10 mL (10 mg/mL) single-dose vials to ensure dosing accuracy and drug effectiveness.

1. Recommended dose:The recommended dose of Tevimbra is 200mg, and patients need to be injected intravenously every 3 weeks. Treatment can be continued until disease progression or unacceptable toxicity. During the first infusion, it is recommended to complete the infusion within 60 minutes to observe the patient's tolerance to the drug. If the patient tolerates subsequent treatments well, the infusion time can be shortened to 30 minutes. This flexible infusion protocol helps improve patient comfort while ensuring the drug is most effective in the body.

2. Dose adjustment: In clinical practice, dose adjustment is an important part of managing adverse reactions during Tevimbra treatment. Generally, it is not recommended to reduce the dose of Tevimbra. If a patient experiences a serious immune-mediated adverse reaction (e.g., Grade 3), Tevimbra should be temporarily discontinued to allow for appropriate monitoring and intervention. Permanent discontinuation of Tevimbra may need to be considered in the event of life-threatening (Grade 4) immune-mediated adverse reactions, or recurrent severe (Grade 3) immune-mediated reactions requiring systemic immunosuppressive therapy. Additionally, if a patient is unable to reduce the steroid dose to 10 mg per day or less of prednisone equivalent within 12 weeks of starting steroid therapy, this may also be an important indication for discontinuation of Tevimbra therapy.

During Tevimbra treatment, patients should maintain close communication with their doctors and promptly report any signs of discomfort or side effects. Regular follow-up and evaluation are essential to promptly adjust treatment plans, manage side effects, and improve treatment effectiveness. At the same time, patients also need to cooperate with doctors to conduct necessary laboratory tests, such as blood routine and liver function monitoring, to ensure safe medication.

Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a##